TECENTRIQ (atezolizumab)

TherapyGenentech

TECENTRIQ (atezolizumab) from Genentech is a PD-L1–directed immunotherapy used across multiple tumor types.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and TECENTRIQ. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where TECENTRIQ is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Urothelial Cancer Solid Tumor · Bladder	PD-L1 protein expression (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area)		View testing pathway →
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung	PD-L1 protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%])		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for TECENTRIQ.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering TECENTRIQ for eligible patients.

Test

Ventana PD-L1 (SP142) Assay

Ventana Medical Systems, Inc. (Roche Diagnostics)

Method

IHC

Specimen

Tissue (FFPE)

2 approvalsView test profile →

Test

Ventana PD-L1 (SP263) Assay

Ventana Medical Systems, Inc. (Roche Diagnostics)

Method

IHC

Specimen

Tissue (FFPE)

1 approvalView test profile →

This view is scoped to TECENTRIQ (atezolizumab). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.